Telix Pharmaceuticals Appoints Mr. Richard Valeix as EMEA President
02 mai 2021 19h15 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and HERSTAL, Belgium, May 02, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Mr. Richard Valeix has joined the Telix...
The NOBLE Registry – An International Collaboration to Develop iPSMA SPECT Imaging for Prostate Cancer
20 avr. 2021 10h32 HE
|
Telix Pharmaceuticals Limited
BRUSSELS, Belgium and MELBOURNE, Australia, April 20, 2021 (GLOBE NEWSWIRE) -- The Oncidium Foundation, a non-profit organisation created to promote and support the development of...
First US Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
24 janv. 2021 17h55 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Jan. 24, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that the first patients have been dosed in...
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine
29 nov. 2020 21h07 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and BAAR, Switzerland, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into an agreement with Scintec...
Telix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
01 nov. 2020 23h11 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and HONG KONG, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into a strategic licence and...
First Patient Dosed in Phase I/II Trial of Renal Cancer Imaging Product in Japan
17 août 2020 20h00 HE
|
Telix Pharmaceuticals Limited
TOKYO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that...
Telix Japan Signs MOU with ATOX to Use IRE ELiT 68Ge/68Ga-Generator for Phase I Study of Prostate Cancer Diagnostic Imaging
27 juil. 2020 02h21 HE
|
Telix Pharmaceuticals Limited
TOKYO, July 27, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce it has...
Telix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study
07 août 2019 20h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and SYDNEY, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...
Telix Pharmaceuticals and German Cancer Research Center (DKFZ) Enter into Collaboration and Option Agreement for Image-Guided Prostate Surgery
04 août 2019 20h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and HEIDELBERG, Germany, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused...
Telix Pharmaceuticals e Grupo RPH firmam Contrato de Manufatura e Distribuição para a LATAM
02 juil. 2019 20h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Austrália e PORTO ALEGRE, Brasil, July 02, 2019 (GLOBE NEWSWIRE) -- A Telix Pharmaceuticals Limited (ASX.TLX) ( “Telix”, a “Empresa”), uma empresa biofarmacêutica de fase clínica...